Background
==========

The *PIN1*gene encodes an essential peptidyl-prolyl *cis/trans*isomerase (PPIase; EC 5.2.1.8) which has a profound impact on key proteins involved in the regulation of cell cycle \[[@B1]\]. The human *PIN1*gene is mapped to chromosome 19p13 \[[@B2]\]. Catalyzing conformational changes in substrates after phosphorylation, Pin1 recognizes phospho-serine or phospho-threonine bonds followed by proline (pSer/Thr-Pro motifs) and plays a vital role in protein folding or refolding \[[@B3]\]. Through isomerization Pin1 can modulate the conformation of protein substrates, changing their enzymatic activity which leads to alteration in different cell function \[[@B1]\].

Pin1 enzyme activity is important for oncogenic and cell-signalling pathways *via*conformational changes following phosphorylation of many molecules (e.g. Bcl-2, p53, c-Jun, beta-catenin, cyclin D1 and RAF kinase) \[[@B4]-[@B7]\]. The Pin1-regulated alteration in protein interactions and stability have been shown to be associated with cell transformation and progression of certain types of human tumours (e.g., prostate, colon, lung, ovary and breast cancers, and lymphoma) \[[@B8]-[@B10]\]. It has also been reported that inhibition of Pin1 function in human tumour cells, using Pin1 antisense RNA, induces mitotic arrest and apoptosis \[[@B11]\]. Further studies indicate that Pin1 plays a critical role in cell restriction points - particularly in G1/S phase; Pin1 modulates some important regulators of that cell cycle point, e.g. cyclin D1 and its upstream transcriptional factors. The increased Pin1 expression correlates significantly with overexpression of cyclin D1 mRNA and protein. Interestingly, Pin1 binds phosphorylated c-Jun, influencing the increase of its transcriptional activity towards cyclin D1 - by activating c-Jun/AP-1 and beta-catenin/T-cell factor (TCF) and, in this way it cooperates with Ras signalling pathway \[[@B4]\].

Pin1 is involved not only in the pathogenesis of human cancer, but - presumably - also in the pathogenesis of asthma and Alzheimer\'s disease \[[@B12]\].

Recently, in some reports - including the study on thyroid tumours - strong correlation between Pin1 and cyclin D1 immunoexpression and/or cyclin D1 mRNA and *PIN1*expression *via*interaction with Wnt signalling pathway has been observed \[[@B13]\]. Moreover, it has been suggested that Pin1 may promote cyclin D1 overexpression directly or through accumulation of beta-catenin in thyroid cancer cells \[[@B13]\].

There are rather scarce reports which are focused on evaluation of PIN1 mRNA expression in thyroid tumours. Therefore, in order to recognize the Pin1 role in the pathogenesis of thyroid gland, we have compared the levels of *PIN1*gene expression in benign and malignant thyroid lesions. We have assessed *PIN1*gene expression in real-time polymerase chain reaction (real-time PCR), two-step RT-PCR (reverse transcriptase-polymerase chain reaction) and we have evaluated the possible correlations between the gene expression and the histopathological variant of examined PTCs (classic, tall-cell, follicular), tumour size grouped according to TNM classification of primary tumours (pT1, pT2, pT3, pT4). We have also decided to estimate the possible relationships between expression of the gene in question and patients\' sex or age.

Materials and methods
=====================

The Ethical Committee of the Medical University of Lodz approved the studies reported in the present article.

Thyroid tissue samples
----------------------

Tumour tissue samples (100-150 mg) were obtained from 70 patients who had undergone surgery treatment at the Centre of Oncology, the Maria Skłodowska-Curie Institute in Gliwice, at the Holy Family Municipal Hospital in Lodz and at the Department of General and Colorectal Surgery, Medical University of Lodz, Poland during the years 2002-2007. Total tumour tissue samples, immediately after resection, were collected into lysis buffer (Buffer RLT, Qiagen Sciences, USA).

Among the studied samples 32 cases of primary papillary thyroid carcinoma - PTC (26 females, 6 males; mean age 41.8 ± 15.7; mean ± SD) were used. Histopathological variants of PTC were as follows: PTC classic variant (20 cases: 17 females, 3 males; mean age 36.5 ± 14.4), PTC follicular variant (9 cases: 6 females, 3 males; mean age 49.9 ± 16.0), PTC tall-cell variant (3 cases: 3 females; mean age 53.3 ± 5.1) (Table [1](#T1){ref-type="table"}). Seven (7) cases of medullary thyroid carcinoma - MTC (6 females, 1 male; mean age 56.0 ± 17.6) and 7 cases of follicular adenoma - FA (6 females, 1 male; mean age 49.4 ± 14.8) were also included in the study. The control group consisted of 24 cases of nodular goitre - NG (22 females, 2 males; mean age 48.9 ± 14.7) (Table [2](#T2){ref-type="table"}).

###### 

Sex, age, histopathological diagnosis of malignant thyroid tumours in the studied patients

  Case number   Sex   Age   Histopathological diagnosis   TNM staging system   American Joint Committee on Cancer (AJCC) grouping system
  ------------- ----- ----- ----------------------------- -------------------- -----------------------------------------------------------
  1             F     23    PTC, classic variant          pT1bNxM0             I
                                                                               
  2             F     38    PTC, classic variant          pT1N0M0              I
                                                                               
  3             F     52    PTC, classic variant          pT2N0M0              II
                                                                               
  4             F     71    PTC, classic variant          pT2N0Mx              II
                                                                               
  5             F     47    PTC, classic variant          pT1aN0M0             I
                                                                               
  6             F     24    PTC, classic variant          pT1N0Mx              I
                                                                               
  7             F     33    PTC, classic variant          pT2aNxMx             II
                                                                               
  8             F     28    PTC, classic variant          pT1bNxMx             I
                                                                               
  9             F     40    PTC, classic variant          pT4N0Mx              IVA
                                                                               
  10            F     17    PTC, classic variant          pT2bN1aM0            III
                                                                               
  11            M     47    PTC, classic variant          pT2aN1aM0            III
                                                                               
  12            M     31    PTC, classic variant          pT2aN0M0             II
                                                                               
  13            F     16    PTC, classic variant          pT2aN0M0             II
                                                                               
  14            F     61    PTC, classic variant          pT2aN0M0             II
                                                                               
  15            F     48    PTC, classic variant          pT4N1aM0             IVA
                                                                               
  16            M     30    PTC, classic variant          pT4N1bM0             IV
                                                                               
  17            F     31    PTC, classic variant          pT1NxMx              I
                                                                               
  18            F     40    PTC, classic variant          pT1aNxMx             I
                                                                               
  19            F     28    PTC, classic variant          pT1aNxMx             I
                                                                               
  20            F     25    PTC, classic variant          pT1aN1aMx            I
                                                                               
  21            F     49    PTC, tall-cell variant        pT2bN0M0             II
                                                                               
  22            F     52    PTC, tall-cell variant        pT4N0M0              IVA
                                                                               
  23            F     59    PTC, tall-cell variant        pT4bN1Mx             IV
                                                                               
  24            F     36    PTC, follicular variant       pT2aNxMx             II
                                                                               
  25            M     28    PTC, follicular variant       pT2N1aMx             II
                                                                               
  26            M     52    PTC, follicular variant       pT3NxMx              III
                                                                               
  27            F     62    PTC, follicular variant       pT1aNxMx             I
                                                                               
  28            F     26    PTC, follicular variant       pT4N1aM0             IVA
                                                                               
  29            F     56    PTC, follicular variant       pT3aN0M0             III
                                                                               
  30            F     68    PTC, follicular variant       pT2bN1aM0            II
                                                                               
  31            M     66    PTC, follicular variant       pT4aN0M0             IVA
                                                                               
  32            F     55    PTC, follicular variant       pT2aN0M0             II
                                                                               
  33            M     74    MTC                           pT4N0M0              IVA
                                                                               
  34            F     32    MTC                           pT1NxMx              I
                                                                               
  35            F     32    MTC                           pT1NxMx              I
                                                                               
  36            F     59    MTC                           pT3N1bM0             III
                                                                               
  37            F     56    MTC                           pT3N0M0              III
                                                                               
  38            F     71    MTC                           pT4N1aM0             IVA
                                                                               
  39            F     68    MTC                           pT3aN0M0             III

###### 

Sex, age, histopathological diagnosis of benign thyroid lesions in the studied patients.

  Case number   Sex   Age   Histopathological diagnosis
  ------------- ----- ----- -----------------------------
  1             F     49    FA
                            
  2             F     52    FA
                            
  3             M     75    FA
                            
  4             F     29    FA
                            
  5             F     41    FA
                            
  6             F     41    FA
                            
  7             F     59    FA
                            
  8             F     40    NG
                            
  9             F     42    NG
                            
  10            F     30    NG
                            
  11            F     48    NG
                            
  12            F     42    NG
                            
  13            F     64    NG
                            
  14            F     69    NG
                            
  15            F     72    NG
                            
  16            F     50    NG
                            
  17            F     51    NG
                            
  18            F     63    NG
                            
  19            F     49    NG
                            
  20            F     49    NG
                            
  21            F     38    NG
                            
  22            M     52    NG
                            
  23            F     31    NG
                            
  24            F     29    NG
                            
  25            M     75    NG
                            
  26            F     28    NG
                            
  27            F     30    NG
                            
  28            F     72    NG
                            
  29            F     50    NG
                            
  30            F     40    NG
                            
  31            F     59    NG

The whole study cohort comprised 70 persons: 60 females and 10 males, the mean age was 46.4 ± 15.8 years (age ranged from 16 to 75 years). Histopathological diagnoses for malignant thyroid lesions, according to WHO Classification of Tumours \[[@B14]\], have been obtained from pathomorphological reports and are presented in Table [1](#T1){ref-type="table"}, together with TNM classification and AJCC stage groupings \[[@B15]\].

In the study design, macroscopically unchanged thyroid tissue served for the reference standard (calibrator).

Isolation of total RNA and reverse transcription (RT)
-----------------------------------------------------

Total RNA was extracted from fresh tisssues, using RNeasy Protect Midi Kit, (Qiagen, Hilden, Germany), according to the manufacturer\'s recommendations. RNA concentration was spectrophotometrically assessed by measuring absorbance at 260 and 280 nm (Ultraspec 2000 UV/Visible Spectrophotometer, Pharmacia Biotech, Sweden).

Afterwards the reverse transcription (RT) was performed in a Personal Thermocycler (Eppendorf, Germany), using 1 μg of total RNA in the presence of 50 μM of oligo d(T)16 and Reverse Transcriptase MultiScribe™ (50 U/μl) in a total volume of 30 μl, including also: 10× TaqMan RT Buffer (containing 100 mM Tris-HCL pH 8.3, 500 mM KCL), MgCl~2~solution (25 mM), dNTPs mixture (10 mM), RNAse Inhibitor (20 U/μl), and nuclease-free water (TaqMan Reverse Transcriptase Reagents, Applied Biosystems, Foster City, CA, USA). The reactions were conducted for 10 minutes at 25°C, followed by 30 minutes at 48°C, afterwards the samples were heated for 5 min to 95°C, and next placed at 4°C. The cDNA concentration and purity were spectrophotometrically assessed by measuring absorbance at 260 and 280 nm (Ultraspec 2000 UV/Visible Spectrophotometer, Pharmacia Biotech, Sweden).

Quantitative analysis of the relative amount of PIN1 mRNA by real-time PCR
--------------------------------------------------------------------------

An established Relative Quantification Polymerase Chain Reaction (RQ-PCR) assay for PIN1 mRNA expression was conducted in ABI PRISM 7500 Sequence Detection System (Applied Biosystems), according to the manufacturer\'s protocol. The PCR reactions for *PIN1*gene were run with 50 ng of cDNA in a total volume of 50 μl, using TaqMan^®^Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and the predesigned and labelled primer/probe set (Assays-on-Demand™ Gene Expression assay mix, Hs01598309_ml, Applied Biosystems). After initial incubation at 50°C for 2 min to allow uracil-N-glycosylase (UNG) digestion, and at 95°C for 10 min to activate the AmpliTaq Gold^®^DNA polymerase, both of them were provided by the Universal PCR Master Mix, the samples were amplified through 40 biphasic cycles of 95°C for 15 sec and 60°C for 1 min (Table [3](#T3){ref-type="table"}).

###### 

Real-time PCR conditions for *PIN1*gene amplification.

  Times and temperatures                                                  
  ---------------------------- ----------------------- ------------------ --------------------------
  **Initial setup**            **Each of 40 cycles**                      
                                                                          
                                                       **Denaturation**   **Annealing/Elongation**
                                                                          
  HOLD                         HOLD                    CYCLE              
                                                                          
  UNG activation 2 min, 50°C   10 min, 95°C            15 s, 95°C         1 min, 60°C

Macroscopically unchanged thyroid tissue was used as a calibrator (standard sample). Amplification reactions were done in triplicate for each sample (cDNA from the same PCR reaction but in separate wells). Controls with no template cDNA were used with each assay (negative control).

The expression levels of *β-actin*gene (*ACTB*) were measured, as endogenous control (reference gene), using the appropriate Assays-on-Demand™ Gene Expression product (Hs99999903_ml, Applied Biosystems Foster City, CA, USA).

Both gene expressions were measured for each thyroid lesion sample in the same PCR reaction but in separate wells.

Assays-on-Demand™ Gene Expression product consists of 20 × mix of unlabelled PCR primers (18 μM for each) and TaqMan^®^MGB probes (5 μM) with FAM™ (6-carboxy-fluorescein) at the 5\' end as the reporter dye, and a non-fluorescent quencher (TAMRA, 6-carboxy-tetramethylrhodamine) at the 3\' end. The two-minute, 50°C step was required for optimal AmpErase^®^UNG activity when TaqMan^®^Universal PCR Master Mix (P/N 4304437) was used.

The fluorescence signal was measured in real-time PCR in the extension phase of the PCR reaction, and the measurement, proportional to the quantity of sample cDNA in the reaction, was plotted as an amplification curve against cycle number. A threshold value of fluorescence in the exponential part of the amplification curve was selected, and - for each sample - the number of cycles was measured, which was needed by the signal to reach the threshold (threshold cycle, C~T~). The larger were the quantities of the starting material, the lower were C~T~values.

Data analysis
-------------

Data analysis of relative gene expression was performed with the Taq-Man SDS analysis software on an ABI PRISM 7500 Sequence Detection System (Applied Biosystems), and the results were exported to Excel sheets for further processing.

Fluorescence emission data were determined as C~T~values for each reaction and, for each sample, triplicate C~T~values were averaged. The average C~T~value for *β-actin*was subtracted from the average *PIN1*C~T~value to yield the ΔC~T~value (ΔC~T~= C~T~target - C~T~reference). Normalization to the reference gene (*β-actin*) has been necessary to account for the variabilities in sample quantity and quality, and for the variabilities in PCR efficiency among samples. The assay, described in this report, involves the determination of a ΔΔC~T~value. This is calculated by: ΔΔC~T~= ΔC~T~test sample - ΔC~T~calibrator sample. The higher is the ΔΔC~T~value, the lower is the expression of *PIN1*in the specimen. Fold-differences, representing relative expression results, are calculated using the following equation: relative fold increase = 2^-ΔΔC^[T]{.smallcaps}. In order to evaluate the analytical sensitivity, specificity, and accuracy of the assay, serial dilutions were performed.

Statistical analysis
--------------------

The data were statistically analyzed, using Newman-Keuls\' multiple comparison test followed by Kruskal-Wallis\' test, in order to compare the level of expression values (RQ) among the four studied independent groups (PTC, MTC, FA, NG). Basic measures of location (i.e. mean, median), measures of dispersion (SD, SEM), and minimum and maximum values were calculated to provide detailed descriptions of gene expressions in selected groups. Additionally, box-and-whiskers plots were introduced to display the difference in gene expressions levels in different samples.

The Kruskal-Wallis\' test was used to compare the level of expression values (RQ) among three variants of PTC (PTC v. classic, PTC v. tall-cell, PTC v. follicular). The Spearman\'s rank correlation coefficient and U Mann-Whitney\'s test were performed in order to correlate the level of expression of *PIN1*gene (RQ values) with examined parameters (age, sex, tumour size, classified according to TNM definition of primary tumours - pT1, pT2, pT3, pT4).

The accepted level of statistical significance was at p \< 0.05. The results are presented as means ± SEM and means ± SD values.

Statistica for Windows 7.0 program was applied for calculations.

Results
=======

The specimens were amplified in the ABI PRISM 7500 Sequence Detection System in reaction, containing primers and probes for *PIN1*gene and a control gene, *β-actin*. The Sequence Detection System software, provided with the instrument, analyses the fluorescence data, generated during the reaction, and calculates the cycle number at which fluorescence crosses the threshold value (C~T~). Triplicate amplifications of the sample produced nearly identical, overlapping curves, from which C~T~values were calculated.

In our experiment low C~T~values for *PIN1*gene in all malignant thyroid tissues (PTC - 32 and MTC - 7 specimens) were observed.

The assay, described in this paper, was based on the determination of a ΔΔC~T~value (ΔΔC~T~method) for each sample (the greater was the ΔΔC~T~value, the lower was the expression of *PIN1*gene) and on calculating the difference in *PIN1*expression level between tumour sample and calibrator (RQ value). The results for calculated RQ in the studied groups (PTC, MTC, FA, NG) are presented in Table [4](#T4){ref-type="table"}. The RQ value for PTC, classic variant, ranged from 0.441 to 52.279 (the mean RQ was 8.43); for PTC, follicular variant, ranged from 0.804 to 9.124 (the mean RQ was 3.03) and for PTC, tall-cell variant, ranged from 0.363 to 12.616 (the mean RQ was 6.42).

###### 

The expression level (RQ) of *PIN1*gene, calculated by the ΔΔC~T~method in the studied groups.

  Group   No. of cases   Mean RQ   Range of RQ values
  ------- -------------- --------- --------------------
  PTC     32             6.72      0.363-52.279
                                   
  MTC     7              5.55      0.917-19.408
                                   
  FA      7              2.79      0.511-8.207
                                   
  NG      24             2.15      0.322-13.153

Kruskal-Wallis\' test, applied for RQ comparison between the four studied groups (PTC, MTC, FA, NG), showed statistically significant differences (p = 0.0233) among them (Figure [1](#F1){ref-type="fig"}). The results of Newman-Keuls\' multiple comparison test revealed statistically significant differences in RQ values only between the PTC group (higher RQ values) and the control group - NG (p = 0.031977). In cases of other groups, the differences in RQ values were not significant (p \> 0.05) (Table [5](#T5){ref-type="table"}). Similarly, the results of Kruskal-Wallis\' test did not show any significant differences among the particular variants of PTC (PTC v. classic, PTC v. tall-cell, PTC v. follicular) (p = 0.9501) (Figure [2](#F2){ref-type="fig"}). Additionally, in the whole studied group of PTCs, no correlations were found between *PIN1*expression level and patients\' sex, age or tumour size (p \> 0.05). The results of Mann-Whitney\'s U test confirmed no significant differences in RQ values between the PTC group and MTC group (p = 0.6873) (Figure [3](#F3){ref-type="fig"}).

###### 

Statistical analysis of results - comparison of RQ value among the four studied groups (PTC, MTC, FA, NG). Newman-Keuls\' test, p - level of significance.

            PTC            MTC        FA         NG
  --------- -------------- ---------- ---------- --------------
  **PTC**                  1.000000   1.000000   **0.031977**
                                                 
  **MTC**   1.000000                  1.000000   0.154248
                                                 
  **FA**    1.000000       1.000000              1.000000
                                                 
  **NG**    **0.031977**   0.154248   1.000000   

![**Box-and-whisker plots, representing the expression of *PIN1* gene in the studied groups (PTC, MTC, FA, NG)**. Results are calculated as RQ values. Whiskers represent means ± SD (standard deviation) for particular groups. Boxes represent means ± SEM (standard error of mean). The data were statistically analyzed, using Newman-Keuls\' multiple comparison test, followed by Kruskal-Wallis\' test, in order to compare the level of expression values (RQ) among the four studied independent groups, p \< 0.05; \* - p \< 0.031977 (Neuman-Keuls\' test).](1756-6614-4-4-1){#F1}

![**Box-and-whisker plots, representing the difference in the expression of *PIN1* gene in the variants of PTC (PTC v. classic, PTC v. tall-cell, PTC v. follicular)**. Results are calculated as RQ values; no significant differences among studied groups are shown. Whiskers represent means ± SD (standard deviation) for particular groups. Boxes represent means ± SEM (standard error of mean). The results were statistically analyzed using Kruskal-Wallis\' test, p = 0.9501.](1756-6614-4-4-2){#F2}

![**Box-and-whisker plots, representing the difference in the expression of *PIN1* gene between the PTC group and the MTC group**. Results are calculated as RQ values; no significant differences between studied groups are demonstrated. Whiskers represent means ± SD (standard deviation) for particular groups. Boxes represent means ± SEM (standard error of mean). The results were statistically analyzed using Mann-Whitney\'s U test, p = 0.6873.](1756-6614-4-4-3){#F3}

Discussion
==========

The molecular pathogenesis of thyroid cancer is very complex and still unclear. Recent molecular studies on thyroid carcinogenesis have proved that many specific genetic alterations in protooncogenes are associated with development of thyroid cancer \[[@B16],[@B17]\]. The mutational activation of MAPK/ERK signalling pathway is crucial to understand the carcinogenesis in the thyroid. The mutations of genes coding effectors of MAPK/ERK pathway (*RET*, *RAS*, *NTRK1*, *BRAF*) which rarely overlap, may be identified in more than 70% of PTC cases \[[@B18]-[@B20]\]. Additionally, the chromosomal rearrangements (*RET/PTC*or *Trk*) appear to be of crucial importance in activation of MAPK/ERK pathway \[[@B21],[@B22]\].

Despite the fact that constitutive activation of the above mentioned pathway is a very important for the development of thyroid cancer, many other molecular regulatory mechanisms, involved in thyroid cancer transformation, are recognized.

In our study, we have examined whether the *PIN1*gene participates in thyroid carcinogenesis.

The phosphorylation of proteins on serine or threonine residues preceding proline (pSer/Thr-Pro motifs), catalized by the peptidyl-prolyl *cis/trans*isomerase Pin1, has been confirmed as a major cell transformation mechanism activating different oncogenic pathways in many types of human tumours (including thyroid cancer) \[[@B9],[@B13],[@B23],[@B24]\]. In immunohistochemical studies of thyroid tumours, as well as of other types of cancers (e.g., oral squamous carcinoma), high Pin1 expression promotes cyclin D1 overexpression, directly or through accumulation of beta-catenin \[[@B13],[@B25]\]. It has been reported that *PIN1*expression is regulated by the transcription factor E2F and Neu/Ras signalling. The enhanced expression and stability of cyclin D1 by transcriptional activation and/or posttranslational stabilization by *PIN1*gene or Pin1 protein may lead to cell proliferation and transformation. Therefore, *PIN1*might be a crucial factor in modulating upregulation of cyclin D1 level by *Neu/Ras*oncogenic signalling \[[@B7],[@B26]\].

Bearing in mind all these facts, in our present study, we have assessed *PIN1*gene expression level in benign and malignant thyroid lesions. In our earlier study, we demonstrated that *cyclin D1*gene expression levels were higher in malignant thyroid tumours (PTC, MTC), when compared to those in NG or FA groups \[[@B27]\]. Our present results have revealed statistically significant differences in expression of PIN1 mRNA between PTC group and benign thyroid lesions (FA, NG) (higher RQ value in PTC). It should be stressed that our data are in accordance with observations of other authors \[[@B13]\]. Nakashima et al. \[[@B13]\] have observed overexpression of cyclin D1 mRNA in PTC (thyroid tumours from a radiocontaminated area), taking course with high expression of *PIN1*gene. In the quoted paper, correlation between high Pin1 protein level and cyclin D1 immunoexpression level in PTC has also been confirmed \[[@B13]\]. It is important that Pin1 can promote cyclin D1 overexpression directly or through beta-catenin stabilization \[[@B6],[@B13]\]. Our present results, which have focused on PIN1 mRNA expression, as well as our earlier data, concerning cyclin D1 mRNA overexpression in thyroid malignancy, may suggest that one of the major regulatory mechanisms in cell transformation in thyroid carcinogenesis is *PIN1*gene activity \[[@B27]\]. It is tempting to speculate that *PIN1*gene positively regulates *cyclin D1*gene function not only through posttranslational stabilization but also by an effect on transcriptional level.

In our present study, we have applied real-time relative quantification PCR assay for PIN1 mRNA expression and, employing this extremely sensitive and precise method, we have confirmed overexpression of *PIN1*gene in PTC. These results may suggest a diagnostic utility of PIN1 mRNA expression - as a malignant lesion marker - for thyroid PTC. However, the results should be confirmed in larger number of PTC cases. The utility of *PIN1*gene may be - in future - very crucial for diagnostics and treatment of thyroid cancer (especially of PTC), based on the facts that overexpression of Pin1 has been found to be an excellent prognostic marker in some other human cancers (e.g., prostate, breast, colorectal cancers) \[[@B8],[@B10],[@B23]\]. In these immunohistochemical studies, strong relationship between Pin1 protein level and clinical outcome has been observed \[[@B8],[@B10],[@B23]\]. Unfortunately, it is difficult to discuss the relationship between PIN1 mRNA and prognosis in PTC, because - according to our knowledge - there were no reported studies, focusing on the evaluation of *PIN1*gene expression in association with pathological features and clinical outcome of PTC, so far. Our present data have not documented any significant differences in the expression level of PIN1 mRNA among the particular variants of PTC (classic vs. tall-cell, vs. follicular variants). Moreover, no correlations were found between *PIN1*expression level and patients\' sex, age or tumour size in PTC group.

In summary, *PIN1*gene expression may have - in future - certain significance in PTC diagnostics and in understanding its pathogenesis. However, our results - due to the small number of cases - do not yet allow considering *PIN1*gene as a prognostic molecular PTC marker.
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